Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

TitleMetabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.
Publication TypeJournal Article
Year of Publication2018
AuthorsZadra G, Loda M
JournalCold Spring Harb Perspect Med
Volume8
Issue10
Date Published2018 10 01
ISSN2157-1422
KeywordsHumans, Male, Prostatic Neoplasms
Abstract

Cancer cells hijack metabolic pathways to support bioenergetics and biosynthetic requirements for their uncontrolled growth. Thus, cancer can be considered as a metabolic disease. In this review, we discuss the main metabolic features of prostate cancer with a particular focus on the link between oncogene-directed cancer metabolic regulation, metabolism rewiring, and epigenetic regulation. The potential of using metabolic profiling as a means to predict disease behavior and to identify novel therapeutic targets and new diagnostic markers will be addressed as well as the current challenges in metabolomics analyses. Finally, diagnostic and prognostic metabolic imaging approaches, including positron emission tomography, mass spectrometry, nuclear magnetic resonance, and their translational applications, will be discussed. Here, we emphasize how targeting metabolic vulnerabilities in prostate cancer may pave the way for novel personalized diagnostic and therapeutic interventions.

DOI10.1101/cshperspect.a030569
Alternate JournalCold Spring Harb Perspect Med
PubMed ID29229664
PubMed Central IDPMC6169980
Grant ListP50 CA090381 / CA / NCI NIH HHS / United States
R01 CA187918 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700